insights_auto
Waarom is 688235 gestegen 4,06%?
Meer informatiechevron_right
688235:SHA
BeOne Medicines AG
CN¥ 255,98
arrow_upward
+4,06%(+9,99) 1D
16 okt, 15:00:00 GMT+8 · CNY
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor 688235 genereren…
Openen
CN¥ 253,20
Hoog
CN¥ 268,18
Laag
CN¥ 252,09
Beursw.
303,26Â mld.
Gem. vol.
2,81Â mln.
Volume
5,69Â mln.
Koers/winst-verhouding
91,43
52 wk hoog
CN¥ 319,24
52 wk laag
CN¥ 205,51
WPA
CN¥ 2,80
Aantal medewerkers
12K
Openen
CN¥ 253,20
Hoog
CN¥ 268,18
Laag
CN¥ 252,09
Beursw.
303,26Â mld.
Gem. vol.
2,81Â mln.
Volume
5,69Â mln.
Koers/winst-verhouding
91,43
52 wk hoog
CN¥ 319,24
52 wk laag
CN¥ 205,51
WPA
CN¥ 2,80
Aantal medewerkers
12K
Nieuwsartikelen
Van webbronnen en nieuwspartners
ad-hoc-news.de
·
1 uur geleden
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Simply Wall Street
·
16 uur geleden
Is BeOne Medicines (ONC) Undervalued As Earnings Estimates Jump?
Profiel
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Over BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Medewerkers12K
Opgericht28 okt 2010
Hoofdkantoor-
Sector-
Websitebeonemedicines.com